Dr. Meera Mehta says OPAT programs should move away from a “one-size-fits-all” monitoring model and instead tailor laboratory follow-ups based on patient risk factors, antimicrobial toxicity, and quality-of-life considerations. #MADIDxSIDP2026 #IDsky
Meera Mehta, PharmD, says OPAT programs should move away from a “one-size-fits-all” monitoring model and instead tailor laboratory follow-ups based on patient risk factors, antimicrobial toxicity, and...
